Journal
GUT MICROBES
Volume 11, Issue 6, Pages 1833-1841Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19490976.2020.1767464
Keywords
Amyotrophic lateral sclerosis; als; motor neuron disease; sod1; microbiome; Akkermansia; nicotinamide
Categories
Funding
- Abisch Frenkel Foundation for the Promotion of Life Sciences
- Gurwin Family Fund for Scientific Research
- Leona M. and Harry B. Helmsley Charitable Trust
- Crown Endowment Fund for Immunological Research
- Else Kroener Fresenius Foundation
- estate of J. Gitlitz
- estate of L. Hershkovich
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- French National Center for Scientific Research (CNRS)
- V. R. Schwartz Research Fellow Chair
- European Research Council
- Israel Science Foundation
- Helmholtz Foundation
Ask authors/readers for more resources
The intestinal microbiota may be involved, through metabolic gut-brain interactions, in a variety of neurological conditions. In this addendum, we summarize the findings of our recent study investigating the potentially modulatory influence of the microbiome in a transgenic ALS mouse model, and the possible application to human disease. We found that transgenic mice show evidence of dysbiosis, even at the pre-symptomatic stage, and have a more severe disease course under germ-free conditions or after receiving broad-spectrum antibiotics. We demonstrated thatAkkermansia muciniphilaameliorated the disease in mice and that this may be due to the production of nicotinamide. We then conducted a preliminary study in human ALS and identified functionally similar alterations within the metagenome. Furthermore, we found that patients with ALS had lower systemic and CSF levels of nicotinamide, suggesting that the changes observed in the mouse model may be relevant to human disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available